查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1566981

長春西汀市場：依產品類型、通路分類：2024-2033 年全球機會分析與產業預測

Vinpocetine Market By Product Type (Tablet, Injection) , By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

長春西汀市場

2023年長春西汀市值為2億美元，預計2024年至2033年複合年成長率為3.5%，到2033年將達3億美元。

長春西汀是一種合成化學品，類似於從長春花植物中提取的天然化合物。這種化合物是一種多促效劑，用於治療多種病症和疾病，包括頭部外傷、中風、帕金森氏症期間的失智症、與老齡化相關的記憶力衰退和阿茲海默症。長春西汀的主要作用機轉是促進腦血流量，進而改善大腦的營養和氧氣供應。由於其出色的安全性，這種化學物質現在以食品補充劑的形式提供，以增強認知和記憶力。

認知障礙的盛行率不斷上升，特別是由於老年人口的迅速增加，正在顯著推動長春西汀市場的成長。此外，隨著及時預防神經退化性疾病意識的增強，越來越多的人開始服用膳食食品作為預防措施，從而增加了對長春西汀的需求。營養食品的激增顯著增加了市場的成長。目前有一個研究趨勢是將長春西汀用於認知支持以外的目的。該化學物質正在測試用於治療動脈粥狀硬化和肺纖維化中肺泡上皮細胞損傷等多種疾病。這種應用的擴展預計將為市場開拓帶來新的細分市場。

然而，由於其分類和功效，這種化學物質在多個國家面臨各種監管障礙，這限制了市場的廣泛成長。此外，還有幾種治療阿茲海默症和失智症的潛在替代藥物正在阻礙市場開拓。例如，美國食品藥物管理局最近核准了新藥lecanemab，一種抗澱粉樣蛋白單株抗體，用於治療癡呆失智症。該藥物透過與澱粉樣蛋白斑塊（失智症的標誌）結合，專門針對失智症的易感性。各種研究都提出了lecanemab的功效，這使其成為長春西汀市場擴張的挑戰。

按部門審查

長春西汀市場分為產品類型、通路和地區。依產品類型分類，市場分為錠劑和注射劑。依銷售管道可分為零售藥局、醫院藥局、網路藥局。從區域來看，分析涵蓋北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

從產品類型來看，錠劑細分市場將在 2023 年佔據較高的市場。

從分銷通路來看，2023年零售藥市場佔有率較高。

從地區來看，北美在長春西汀市場佔據主導地位。

可以使用此報告進行客製化（需要額外費用和時間表）

  • 新產品開發/主要企業產品矩陣
  • 監管指引
  • 根據客戶興趣新增其他公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • 主要參與企業的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章長春西汀市場：依產品類型

  • 市場概況
  • 錠劑
  • 注射

第5章長春西汀市場：依通路分類

  • 市場概況
  • 零售藥房
  • 醫院藥房
  • 網路藥房

第6章 長春西汀市場：依地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國長春西汀市場
    • 加拿大長春西汀市場
    • 墨西哥長春西汀市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國長春西汀市場
    • 法國長春西汀市場
    • 英國長春西汀市場
    • 義大利長春西汀市場
    • 西班牙長春西汀市場
    • 其他歐洲長春西汀市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 日本長春西汀市場
    • 中國長春西汀市場
    • 澳洲長春西汀市場
    • 印度長春西汀市場
    • 韓國長春西汀市場
    • 其他亞太地區長春西汀市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西長春西汀市場
    • 沙烏地阿拉伯的長春西汀市場
    • 南非長春西汀市場
    • 其他拉丁美洲/中東/非洲長春西汀市場

第7章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第8章 公司簡介

  • Northeast Pharmaceutical Group Co., Ltd.
  • COVEX
  • Runhong
  • Liaoning Zhiying
  • Sun Pharmaceuticals Industries Ltd
  • Welman
  • Micro Labs Ltd
  • Gedeon Richter Plc.
簡介目錄
Product Code: A324539

Vinpocetine Market

The vinpocetine market was valued at $0.2 billion in 2023 and is projected to reach $0.3 billion by 2033, growing at a CAGR of 3.5% from 2024 to 2033.

Vinpocetine is a synthetic chemical that holds resemblance with a natural compound derived from the plant Vinca minor. The compound is a multi-action agent used to treat various conditions and diseases, including head injuries, stroke, dementia during Parkinson's disease, age-related memory loss, and Alzheimer's disease. The primary action mechanism of vinpocetine involves the enhancement of cerebral blood flow, resulting in improved nutrient and oxygen delivery to the brain. Owing to its remarkable safety profile, the chemical has been made available in the form of dietary supplement for enhanced cognition and memory.

Increase in the prevalence of cognitive disorders, particularly due to exponential growth in the elderly population has significantly driven the growth of the vinpocetine market. In addition, with rising awareness regarding the timely prevention of neurodegenerative diseases, individuals are beginning the consumption of dietary supplements as a precautionary measure, thereby boosting the demand for vinpocetine. The expanding landscape of dietary supplements augments the growth of the market notably. Currently, explorations regarding the applications of vinpocetine beyond its cognitive support are trending. The chemical has been tested for the treatment of diverse conditions such as atherosclerosis and injured alveolar epithelial cells in pulmonary fibrosis. Such expansion of applications is projected to present new segments for market development.

However, the chemical faces different regulatory hurdles in several countries owing to its classification and efficacy, which restrains the widespread growth of the market. Furthermore, several alternative and competent alternatives are available for the treatment of Alzheimer's and dementia, hampering market development. For instance, the U.S. Food and Drug Administration and recently approved the efficacy of a novel drug-lecanemab-an anti-amyloid monoclonal antibody, for the treatment of dementia. The drug particularly targets the elementary causes of the disease by binding to amyloid-beta plaques, the hallmark of the disease. Different studies have advocated for the effectiveness of lecanemab, presenting challenges for the expansion of the vinpocetine market.

Segment Review

The vinpocetine market is segmented into product type, distribution channel, and region. On the basis of product type, the market is bifurcated into tablet and injection. As per distribution channel, it is divided into retail pharmacies, hospital pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of product type, the tablet segment acquired a high stake in the market in 2023.

As per distribution channel, the retail pharmacies segment accounted for a high market share in 2023.

Region wise, North America holds a dominant position in the vinpocetine market.

Competition Analysis

The leading players operating in the global vinpocetine market include Northeast Pharmaceutical Group Co., Ltd., Gedeon Richter, COVEX, Runhong, Liaoning Zhiying, Sun Pharmaceuticals Industries Ltd, Welman, and Micro Labs Ltd. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • New Product Development/ Product Matrix of Key Players
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

  • Tablet
  • Injection

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Northeast Pharmaceutical Group Co., Ltd.
    • COVEX
    • Runhong
    • Liaoning Zhiying
    • Sun Pharmaceuticals Industries Ltd
    • Welman
    • Micro Labs Ltd
    • Gedeon Richter Plc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: VINPOCETINE MARKET, BY PRODUCT TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product Type
  • 4.2. Tablet
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Injection
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: VINPOCETINE MARKET, BY DISTRIBUTION CHANNEL

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Distribution Channel
  • 5.2. Retail Pharmacies
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Hospital Pharmacies
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Online Pharmacies
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: VINPOCETINE MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Product Type
    • 6.2.3. Market Size and Forecast, By Distribution Channel
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Vinpocetine Market
      • 6.2.5.1. Market Size and Forecast, By Product Type
      • 6.2.5.2. Market Size and Forecast, By Distribution Channel
    • 6.2.6. Canada Vinpocetine Market
      • 6.2.6.1. Market Size and Forecast, By Product Type
      • 6.2.6.2. Market Size and Forecast, By Distribution Channel
    • 6.2.7. Mexico Vinpocetine Market
      • 6.2.7.1. Market Size and Forecast, By Product Type
      • 6.2.7.2. Market Size and Forecast, By Distribution Channel
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Product Type
    • 6.3.3. Market Size and Forecast, By Distribution Channel
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Vinpocetine Market
      • 6.3.5.1. Market Size and Forecast, By Product Type
      • 6.3.5.2. Market Size and Forecast, By Distribution Channel
    • 6.3.6. France Vinpocetine Market
      • 6.3.6.1. Market Size and Forecast, By Product Type
      • 6.3.6.2. Market Size and Forecast, By Distribution Channel
    • 6.3.7. UK Vinpocetine Market
      • 6.3.7.1. Market Size and Forecast, By Product Type
      • 6.3.7.2. Market Size and Forecast, By Distribution Channel
    • 6.3.8. Italy Vinpocetine Market
      • 6.3.8.1. Market Size and Forecast, By Product Type
      • 6.3.8.2. Market Size and Forecast, By Distribution Channel
    • 6.3.9. Spain Vinpocetine Market
      • 6.3.9.1. Market Size and Forecast, By Product Type
      • 6.3.9.2. Market Size and Forecast, By Distribution Channel
    • 6.3.10. Rest of Europe Vinpocetine Market
      • 6.3.10.1. Market Size and Forecast, By Product Type
      • 6.3.10.2. Market Size and Forecast, By Distribution Channel
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Product Type
    • 6.4.3. Market Size and Forecast, By Distribution Channel
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Vinpocetine Market
      • 6.4.5.1. Market Size and Forecast, By Product Type
      • 6.4.5.2. Market Size and Forecast, By Distribution Channel
    • 6.4.6. China Vinpocetine Market
      • 6.4.6.1. Market Size and Forecast, By Product Type
      • 6.4.6.2. Market Size and Forecast, By Distribution Channel
    • 6.4.7. Australia Vinpocetine Market
      • 6.4.7.1. Market Size and Forecast, By Product Type
      • 6.4.7.2. Market Size and Forecast, By Distribution Channel
    • 6.4.8. India Vinpocetine Market
      • 6.4.8.1. Market Size and Forecast, By Product Type
      • 6.4.8.2. Market Size and Forecast, By Distribution Channel
    • 6.4.9. South Korea Vinpocetine Market
      • 6.4.9.1. Market Size and Forecast, By Product Type
      • 6.4.9.2. Market Size and Forecast, By Distribution Channel
    • 6.4.10. Rest of Asia-Pacific Vinpocetine Market
      • 6.4.10.1. Market Size and Forecast, By Product Type
      • 6.4.10.2. Market Size and Forecast, By Distribution Channel
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Product Type
    • 6.5.3. Market Size and Forecast, By Distribution Channel
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Vinpocetine Market
      • 6.5.5.1. Market Size and Forecast, By Product Type
      • 6.5.5.2. Market Size and Forecast, By Distribution Channel
    • 6.5.6. Saudi Arabia Vinpocetine Market
      • 6.5.6.1. Market Size and Forecast, By Product Type
      • 6.5.6.2. Market Size and Forecast, By Distribution Channel
    • 6.5.7. South Africa Vinpocetine Market
      • 6.5.7.1. Market Size and Forecast, By Product Type
      • 6.5.7.2. Market Size and Forecast, By Distribution Channel
    • 6.5.8. Rest of LAMEA Vinpocetine Market
      • 6.5.8.1. Market Size and Forecast, By Product Type
      • 6.5.8.2. Market Size and Forecast, By Distribution Channel

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Northeast Pharmaceutical Group Co., Ltd.
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. COVEX
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Runhong
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Liaoning Zhiying
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Sun Pharmaceuticals Industries Ltd
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Welman
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Micro Labs Ltd
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Gedeon Richter Plc.
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments